KYTX
Kyverna Therapeutics, Inc. NASDAQ Listed Feb 9, 2024$8.61
After hrs
$8.69
+0.92%
Mkt Cap $377.0M
52w Low $2.52
54.6% of range
52w High $13.67
50d MA $8.87
200d MA $7.91
P/E (TTM)
—
EV/EBITDA
—
P/B
1.6x
Debt/Equity
0.1x
ROE
-69.5%
P/FCF
-2.4x
RSI (14)
60.60
ATR (14)
$0.43
Beta
2.64
50d MA
$8.87
200d MA
$7.91
Avg Volume
861.1K
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
5980 Horton Street · Emeryville, CA 94608 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 12, 2026 | AMC | -0.75 | -0.66 | +12.0% | 10.23 | +0.6% | +5.4% | -0.4% | -11.6% | -10.0% | +1.9% | — |
| Mar 26, 2026 | AMC | -0.84 | -0.80 | +5.3% | 8.03 | +0.0% | -2.9% | -2.8% | +13.9% | +1.6% | +1.1% | — |
| Nov 12, 2025 | AMC | -0.97 | -0.85 | +12.4% | 7.33 | -1.4% | -11.6% | +6.2% | +4.1% | +9.4% | +5.1% | — |
| Aug 12, 2025 | AMC | -1.00 | -0.97 | +3.0% | 3.02 | +0.7% | +14.9% | +2.0% | -0.8% | +0.9% | -6.8% | — |
| May 13, 2025 | AMC | -1.21 | -1.03 | +14.9% | 2.32 | +0.0% | -7.3% | +1.4% | +6.4% | -10.8% | +15.5% | — |
| Mar 27, 2025 | AMC | -0.87 | -0.88 | -1.1% | 2.36 | -0.4% | -15.3% | -3.5% | +2.6% | +8.6% | -8.4% | — |
| Nov 13, 2024 | AMC | -0.77 | -0.80 | -3.9% | 5.06 | +3.4% | -5.1% | -9.4% | +1.4% | -7.5% | +1.0% | — |
| Aug 12, 2024 | AMC | -0.70 | -0.67 | +4.3% | 6.53 | +6.6% | +7.2% | -3.6% | +3.1% | -3.2% | +3.6% | — |
| May 14, 2024 | AMC | -0.88 | -1.12 | -27.3% | 15.50 | +2.3% | +2.4% | -3.9% | +1.1% | -6.6% | -4.9% | — |
| Feb 8, 2024 | AMC | -3.23 | -26.86 | -731.6% | 30.00 | +0.5% | +0.3% | -0.6% | -0.7% | +0.6% | -0.5% | — |
| Sep 30, 2023 | AMC | — | -0.36 | — | — | — | — | — | — | — | — | — |
| Jun 30, 2023 | AMC | — | -0.30 | — | — | — | — | — | — | — | — | — |
| Mar 31, 2023 | AMC | — | -0.43 | — | — | — | — | — | — | — | — | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.23 | $10.17 | -0.6% | -12.5% | +1.2% | -0.8% | -3.2% | -3.4% |
| Dec 16 | Wells Fargo | Maintains | Overweight → Overweight | — | $10.82 | $10.70 | -1.1% | -5.4% | -32.5% | +1.3% | +2.7% | +13.1% |
| Dec 4 | Morgan Stanley | Maintains | Overweight → Overweight | — | $7.18 | $7.25 | +1.0% | +9.2% | -0.5% | +6.0% | -4.4% | +3.4% |
| Oct 30 | Wells Fargo | Maintains | Overweight → Overweight | — | $7.17 | $7.25 | +1.1% | -5.9% | +3.3% | -1.3% | -7.6% | +9.3% |
| Oct 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.44 | $7.88 | +5.9% | +5.0% | -2.6% | -5.8% | -5.9% | +3.3% |
| Oct 8 | Wells Fargo | Maintains | Overweight → Overweight | — | $5.41 | $5.98 | +10.5% | +32.7% | -1.7% | -6.1% | +4.5% | -2.5% |
| Aug 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.70 | $3.90 | +5.4% | +0.3% | -3.2% | +3.6% | -2.4% | +8.5% |
| May 27 | HC Wainwright & Co. | Upgrade | Neutral → Buy | — | $2.27 | $2.49 | +9.7% | +13.7% | -1.2% | +3.1% | -3.0% | +3.9% |
| Apr 3 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $2.15 | $2.00 | -7.0% | -8.4% | +0.5% | -3.5% | -2.1% | +3.7% |
| Apr 1 | Morgan Stanley | Maintains | Overweight → Overweight | — | $1.93 | $1.91 | -1.0% | +2.6% | +8.6% | -8.4% | +0.5% | -3.5% |
| Nov 20 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $4.08 | $4.20 | +2.9% | +1.0% | -3.2% | +10.0% | +16.4% | -1.0% |
| Nov 15 | Wells Fargo | Maintains | Overweight → Overweight | — | $4.80 | $4.85 | +1.0% | -9.4% | +1.4% | -7.5% | +1.0% | -3.2% |
| Sep 19 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $6.60 | $6.87 | +4.1% | +4.8% | -7.7% | -8.5% | -4.4% | -6.3% |
| Aug 15 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $6.75 | $6.69 | -0.9% | +3.1% | -3.2% | +3.6% | +6.2% | +13.4% |
| Jul 31 | JP Morgan | Maintains | Overweight → Overweight | — | $8.75 | $8.86 | +1.3% | -1.0% | -9.4% | -7.6% | -2.9% | -0.4% |
| Jul 16 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $9.91 | $10.95 | +10.5% | +11.7% | -5.1% | -0.2% | -4.5% | -3.0% |
No insider trades available.
8-K · 5.02
!!! Very High
Kyverna Therapeutics, Inc. -- 8-K 5.02: Executive Change
Kyverna Therapeutics appointed Gregory Martini as CFO effective May 18, 2026, signaling leadership continuity and financial management transition for the biopharmaceutical company's operations.
May 18
8-K · 8.01
!! High
Kyverna Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Eli Lilly acquired Kyverna Therapeutics for an undisclosed amount, expanding its immunology portfolio with Kyverna's cell therapy candidates.
May 4
8-K · 7.01
! Medium
Kyverna Therapeutics, Inc. -- 8-K 7.01: Regulation FD Disclosure
Kyverna Therapeutics reported positive primary analysis results from its KYSA-8 registrational trial for miv-cel in stiff person syndrome, supporting potential regulatory approval and commercialization prospects for this cell therapy.
Apr 22
8-K · 7.01
! Medium
Kyverna Therapeutics, Inc. -- 8-K 7.01: Regulation FD Disclosure
Kyverna Therapeutics will discuss financial results on April 22, 2026, providing investors an opportunity to hear management commentary and ask questions about recent company performance.
Apr 22
8-K · 7.01
! Medium
Kyverna Therapeutics, Inc. -- 8-K 7.01: Regulation FD Disclosure
Kyverna Therapeutics will hold a conference call on April 22, 2026 at 7:00 a.m. ET to discuss results, providing investors opportunity to hear management commentary directly.
Apr 20
8-K
Unknown — 8-K Filing
KYTX's cell therapy pipeline progress and cash position will determine survival through key clinical trial readouts, making investor focus on remaining runway and trial timelines critical for valuation.
Mar 26
8-K · 5.02
!!! Very High
Kyverna Therapeutics, Inc. -- 8-K 5.02: Executive Change
Kyverna Therapeutics appointed Andrew Miller as a Class III director, expanding its board composition to strengthen governance and potentially bringing new strategic expertise to the company.
Feb 24
8-K · 5.02
!!! Very High
Kyverna Therapeutics, Inc. -- 8-K 5.02: Executive Change
Karen Walker's resignation as Chief Technology Officer of Kyverna Therapeutics (KYTX) appears amicable with no operational disputes, though investors should monitor whether the company promptly names a replacement.
Feb 3
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Gilead Sciences, Inc. | 4,126,119 | $39M | — | Dec 2025 |
| 2 | Gordonmd Global Investments Lp | 4,244,818 | $37M | Reduced | Mar 2026 |
| 3 | Morgan Stanley | 2,004,990 | $19M | Added | Dec 2025 |
| 4 | Deerfield Management Company, L.p. | 2,000,000 | $17M | — | Mar 2026 |
| 5 | Aigh Capital Management Llc | 2,000,000 | $17M | Added | Mar 2026 |
| 6 | Vanguard Capital Management Llc | 1,783,342 | $15M | New | Mar 2026 |
| 7 | Millennium Management | 1,005,508 | $9M | Added | Mar 2026 |
| 8 | Woodline Partners Lp | 845,325 | $7M | — | Mar 2026 |
| 9 | D.e. Shaw & Co | 721,581 | $6M | Added | Mar 2026 |
| 10 | Propel Bio Management, Llc | 644,421 | $6M | Reduced | Mar 2026 |
| 11 | Marshall Wace, Llp | 605,512 | $5M | Added | Mar 2026 |
| 12 | Susquehanna International Group, Llp | 577,600 | $5M | Added | Mar 2026 |
| 13 | Ubs Group Ag | 449,750 | $4M | Added | Mar 2026 |
| 14 | Bnp Paribas Financial Markets | 412,032 | $4M | Added | Mar 2026 |
| 15 | Renaissance Technologies Llc | 367,492 | $3M | Added | Mar 2026 |
| 16 | Qube Research & Technologies Ltd | 333,692 | $3M | Added | Mar 2026 |
| 17 | Point72 Asset Management | 222,929 | $2M | Added | Mar 2026 |
| 18 | Jane Street Group, Llc | 182,093 | $2M | Reduced | Dec 2025 |
| 19 | Invesco Ltd. | 186,674 | $2M | New | Mar 2026 |
| 20 | Two Sigma Investments, Lp | 181,615 | $2M | Reduced | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$377.0M
Enterprise Value
$118.6M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
-0.28x
P/B
1.64x
P/S
—
P/FCF
-2.43x
EV/EBITDA
—
Shares Out
44.3M
Financials (TTM)
Revenue
$0
Net Income
-$156.4M
EBITDA
-$153.6M
Free Cash Flow
-$153.7M
Op Cash Flow
-$153.7M
EPS Basic
$-3.64
EPS Diluted
$-3.28
EPS Forward
$-3.05
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$293.8M
Total Liab.
$61.5M
Total Equity
$232.3M
Cash
$279.3M
LT Debt
$24.7M
Book Value/Sh
$5.25
Debt/Equity
0.12x
Current Ratio
7.75
Quick Ratio
7.75
Returns & Growth
ROE
-69.5%
ROA
-54.9%
ROIC
-65.0%
Rev Growth YoY
+0.0%
EPS Growth YoY
-9.3%
Price Returns
2W
-20.7%
1M
-3.2%
3M
+3.8%
6M
+11.1%
12M
+234.1%
Technicals
52W High
$13.67
52W Low
$2.52
50d MA
$8.87
200d MA
$7.91
RSI (14)
60.60
ATR (14)
$0.43
Beta
2.64
Avg Volume
861K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$32.67
High
$33.00
Low
$32.00
Median
$33.00
Data updated apr 25, 2026 6:19pm
· Source: financialmodelingprep.com